{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:03:18Z","timestamp":1763755398824,"version":"3.45.0"},"reference-count":45,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2016,3,1]]},"DOI":"10.1188\/16.onf.190-197","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T14:55:11Z","timestamp":1455893711000},"page":"190-197","source":"Crossref","is-referenced-by-count":5,"title":["Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors"],"prefix":"10.1188","volume":"43","author":[{"given":"Jochen","family":"Hefner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Johanna","family":"Csef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Kunzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Apperley, J.F. (2015). Chronic myeloid leukaemia. Lancet, 385, 1447\u20131459.","DOI":"10.1016\/S0140-6736(13)62120-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Baccarani, M., Castagnetti, F., Gugliotta, G., Palandri, F., & Rosti, G. (2014). Treatment recommendations for chronic myeloid leukemia. Mediterranean Journal of Hematology and Infectious Diseases, 6, e2014005.","DOI":"10.4084\/mjhid.2014.005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Baccarani, M., Rosti, G., de Vivo, A., Bonifazi, F., Russo, D., Martinelli, G., . . . Tura, S. (2002). A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood, 99, 1527\u20131535.","DOI":"10.1182\/blood.V99.5.1527"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., . . . Baccarani, M. (2001). Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood, 98, 3074\u20133081.","DOI":"10.1182\/blood.V98.10.3074"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Brintzenhofe-Szoc, K.M., Levin, T.T., Li, Y., Kissane, D.W., & Zabora, J.R. (2009). Mixed anxiety\/depression symptoms in a large cancer cohort: Prevalence by cancer type. Psychosomatics, 50, 383\u2013391.","DOI":"10.1176\/appi.psy.50.4.383"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Burgess, C., Cornelius, V., Love, S., Graham, J., Richards, M., & Ramirez, A. (2005). Depression and anxiety in women with early breast cancer: Five year observational cohort study. BMJ, 330, 702.","DOI":"10.1136\/bmj.38343.670868.D3"},{"key":"7","unstructured":"Deck, R., & R\u00f6ckelein, E. (1999). [On the elicitation of socio-demographic and socio-medical Indicators in research associations of rehabilitation sciences]. DRV-Schriften, 16, 84\u2013102."},{"key":"8","doi-asserted-by":"crossref","unstructured":"D\u2019Souza, V., Blouin, E., Zeitouni, A., Muller, K., & Allison, P.J. (2013). An investigation of the effect of tailored information on symptoms of anxiety and depression in head and neck cancer patients. Oral Oncology, 49, 431\u2013437.","DOI":"10.1016\/j.oraloncology.2012.12.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Efficace, F., Breccia, M., Saussele, S., Kossak-Roth, U., Cardoni, A., Caocci, G., . . . Sprangers, M. (2012). Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. Annals of Hematology, 91, 1371\u20131381.","DOI":"10.1007\/s00277-012-1458-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini, C., Antolini, L., Mahon, F.X., Guilhot, F., Deininger, M., Fava, C., . . . Kim, D.W. (2011). Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. Journal of the National Cancer Institute, 103, 553\u2013561.","DOI":"10.1093\/jnci\/djr060"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Garcia, S. (2014). The effects of education on anxiety levels in patients receiving chemotherapy for the first time: An integrative review. Clinical Journal of Oncology Nursing, 18, 516\u2013521.","DOI":"10.1188\/14.CJON.18-05AP"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Gater, A., Heron, L., Abetz-Webb, L., Coombs, J., Simmons, J., Guilhot, F., & Rea, D. (2012). Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leukemia Research, 36, 817\u2013825.","DOI":"10.1016\/j.leukres.2012.01.021"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.L., Maloisel, F., . . . Tanzer, J. (1997). Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New England Journal of Medicine, 337, 223\u2013229.","DOI":"10.1056\/NEJM199707243370402"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Hefner, J., Kapp, M., Drebinger, K., Dannenmann, A., Einsele, H., Grigoleit, G.U., . . . Mielke, S. (2014). High prevalence of distress in patients after allogeneic hematopoietic SCT. Bone Marrow Transplant, 49, 581\u2013584.","DOI":"10.1038\/bmt.2013.228"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Henderson, V.P., Clemow, L., Massion, A.O., Hurley, T.G., Druker, S., & Hebert, J.R. (2012). The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: A randomized trial. Breast Cancer Research and Treatment, 131, 99\u2013109.","DOI":"10.1007\/s10549-011-1738-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Herschbach, P., Berg, P., Dankert, A., Duran, G., Engst-Hastreiter, U., Waadt, S., . . . Henrich, G. (2005). Fear of progression in chronic diseases: Psychometric properties of the Fear of Progression Questionnaire. Journal of Psychosomtic Research, 58, 505\u2013511.","DOI":"10.1016\/j.jpsychores.2005.02.007"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Herschbach, P., Book, K., Dinkel, A., Berg, P., Waadt, S., Duran, G., . . . Henrich, G. (2010). Evaluation of two group therapies to reduce fear of progression in cancer patients. Supportive Care in Cancer, 18, 471\u2013479.","DOI":"10.1007\/s00520-009-0696-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Herschbach, P., & Dinkel, A. (2014). Fear of progression. Recent Results in Cancer Research, 197, 11\u201329.","DOI":"10.1007\/978-3-642-40187-9_2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Hochhaus, A. (2011). Educational session: Managing chronic myeloid leukemia as a chronic disease. Hematology, 2011, 128\u2013135.","DOI":"10.1182\/asheducation-2011.1.128"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Holland, J.C., Andersen, B., Breitbart, W.S., Buchmann, L.O., Compas, B., Deshields, T.L., . . . Freedman-Cass, D.A. (2013). Distress management. Journal of the National Comprehensive Cancer Network, 11, 190\u2013209.","DOI":"10.6004\/jnccn.2013.0027"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Jabbour, E., & Kantarjian, H. (2014). Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. American Journal of Hematology, 89, 547\u2013556.","DOI":"10.1002\/ajh.23691"},{"key":"22","unstructured":"Jabbour, E.J., Bixby, D., & Akard, L.P. (2012). Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia. Clinical Advances in Hematology Oncology, 10(12, Suppl. 22), 1\u201316."},{"key":"23","doi-asserted-by":"crossref","unstructured":"Jabbour, E.J., Kantarjian, H., Eliasson, L., Cornelison, A.M., & Marin, D. (2012). Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. American Journal of Hematology, 87, 687\u2013691.","DOI":"10.1002\/ajh.23180"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Jayakar, V. (2012). Chronic myeloid leukemia: In pursuit of perfection. South Asian Journal of Cancer, 1, 16\u201324.","DOI":"10.4103\/2278-330X.96498"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O\u2019Brien, S., Wassmann, B., . . . Ottmann, O.G. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New England Journal of Medicine, 354, 2542\u20132551.","DOI":"10.1056\/NEJMoa055104"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., . . . Baccarani, M. (2010). Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 362, 2260\u20132270.","DOI":"10.1056\/NEJMoa1002315"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Kantarjian, H.M., Shah, N.P., Cortes, J.E., Baccarani, M., Agarwal, M.B., Undurraga, M.S., . . . Hochhaus, A. (2012). Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Two-year follow-up from a randomized phase 3 trial (DASISION). Blood, 119, 1123\u20131129.","DOI":"10.1182\/blood-2011-08-376087"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Koch, L., Jansen, L., Brenner, H., & Arndt, V. (2013). Fear of recurrence and disease progression in long-term (>\/= 5 years) cancer survivors. Psycho-Oncology, 22, 1\u201311.","DOI":"10.1002\/pon.3022"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Kris, M.G., Benowitz, S.I., Adams, S., Diller, L., Ganz, P., Kahlenberg, M.S., . . . Petrelli, N.J. (2010). Clinical cancer advances 2010: Annual report on progress against cancer from the American Society of Clinical Oncology. Journal of Clinical Oncology, 28, 5327\u20135347.","DOI":"10.1200\/JCO.2010.33.2742"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Ludman, E.J., McCorkle, R., Bowles, E.A., Rutter, C.M., Chubak, J., Tuzzio, L., . . . Wagner, E.H. (2015). Do depressed newly diagnosed cancer patients differentially benefit from nurse navigation? General Hospital Psychiatry, 37, 236\u2013239.","DOI":"10.1016\/j.genhosppsych.2015.02.008"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Mann, K.S. (2011). Education and health promotion for new patients with cancer. Clinical Journal of Oncology Nursing, 15, 55\u201361.","DOI":"10.1188\/11.CJON.55-61"},{"key":"32","doi-asserted-by":"crossref","unstructured":"McClellan, W., Klemp, J.R., Krebill, H., Ryan, R., Nelson, E.L., Panicker, J., . . . Stegenga, K. (2013). Understanding the functional late effects and informational needs of adult survivors of childhood cancer. Oncology Nursing Forum, 40, 254\u2013262.","DOI":"10.1188\/13.ONF.254-262"},{"key":"33","doi-asserted-by":"crossref","unstructured":"McPhillips, D., Evans, R., Ryan, D., Daneshvar, C., Sarkar, S.A., & Breen, D. (2015). The role of a nurse specialist in a modern lung-cancer service. British Journal of Nursing, 24(Suppl. 4), S21\u2013S27.","DOI":"10.12968\/bjon.2015.24.Sup4.S21"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Mehnert, A., Herschbach, P., Berg, P., Henrich, G., & Koch, U. (2006). [Fear of progression in breast cancer patients\u2014Validation of the short form of the Fear of Progression Questionnaire]. Zeitschrift fur Psychosomatische Medizin und Psychotherapie, 52, 274\u2013288.","DOI":"10.13109\/zptm.2006.52.3.274"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Mehnert, A., Koch, U., Sundermann, C., & Dinkel, A. (2013). Predictors of fear of recurrence in patients one year after cancer rehabilitation: A prospective study. Acta Oncologica, 52, 1102\u20131109.","DOI":"10.3109\/0284186X.2013.765063"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Mo, X.D., Jiang, Q., Xu, L.P., Liu, D.H., Liu, K.Y., Jiang, B., . . . Huang, X.J. (2014). Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant, 49, 576\u2013580.","DOI":"10.1038\/bmt.2013.232"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Noens, L., van Lierde, M.A., De Bock, R., Verhoef, G., Zachee, P., Berneman, Z., . . . Abraham, I. (2009). Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia. Blood, 113, 5401\u20135411.","DOI":"10.1182\/blood-2008-12-196543"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Phillips, K.M., Pinilla-Ibarz, J., Sotomayor, E., Lee, M.R., Jim, H.S., Small, B.J., . . . Jacobsen, P.B. (2013). Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison. Supportive Care in Cancer, 21, 1097\u20131103.","DOI":"10.1007\/s00520-012-1630-5"},{"key":"39","unstructured":"Polat, U., Arpaci, A., Demir, S., Erdal, S., & Yalcin, S. (2014). Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: Impact of patient education before treatment initiation. Journal of Gastrointestinal Oncology, 5, 270\u2013275."},{"key":"40","doi-asserted-by":"crossref","unstructured":"Shields, C.G., Ziner, K.W., Bourff, S.A., Schilling, K., Zhao, Q., Monahan, P., . . . Champion, V. (2010). An intervention to improve communication between breast cancer survivors and their physicians. Journal of Psychosocial Oncology, 28, 610\u2013629.","DOI":"10.1080\/07347332.2010.516811"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Siekkinen, M., Pyrhonen, S., Ryhanen, A., Vahlberg, T., & Leino-Kilpi, H. (2015). Psychosocial outcomes of e-feedback of radiotherapy for breast cancer patients: A randomized controlled trial. Psycho-Oncology, 24, 515\u2013522.","DOI":"10.1002\/pon.3684"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Swanson, J., & Koch, L. (2010). The role of the oncology nurse navigator in distress management of adult inpatients with cancer: A retrospective study. Oncology Nursing Forum, 37, 69\u201376.","DOI":"10.1188\/10.ONF.69-76"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., . . . Sawyers, C.L. (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 354, 2531\u20132541.","DOI":"10.1056\/NEJMoa055229"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Thompson, H. (1877). Middlesex hospital: Case of leucocythaemia. Lancet, 109, 125\u2013126.","DOI":"10.1016\/S0140-6736(02)59712-9"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Trask, P.C., Cella, D., Powell, C., Reisman, A., Whiteley, J., & Kelly, V. (2013). Health-related quality of life in chronic myeloid leukemia. Leukemia Research, 37, 9\u201313.","DOI":"10.1016\/j.leukres.2012.09.013"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/43\/2\/fear-progression-outpatients-chronic-myeloid-leukemia-oral-tyrosine-kinase-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:49Z","timestamp":1763754769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/43\/2\/fear-progression-outpatients-chronic-myeloid-leukemia-oral-tyrosine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1188\/16.onf.190-197","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"type":"print","value":"0190-535X"},{"type":"electronic","value":"1538-0688"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}